Key result
Candesartan significantly reduced VEGF and p22phox gene expression in the retina of 50-week-old diabetic rats, whereas angiotensin II infusion significantly increased these levels.
Why the study?
Does candesartan or angiotensin II affect retinal gene expression of VEGF and p22phox in a type 2 diabetic rat model?
Does candesartan or angiotensin II affect retinal gene expression of VEGF and p22phox in a type 2 diabetic rat model?
Angiotensin II mediates VEGF gene expression via NADPH oxidase in the retina of a type 2 diabetic rat model, an effect that can be attenuated by an angiotensin II receptor blocker.
Preclinical data do not alter ARB prescribing; leaves open human validation of retinal VEGF modulation in diabetes.
PURPOSE: To clarify the involvement of angiotensin II-dependent vascular endothelial growth factor (VEGF) via NADPH oxidase in the retina in spontaneously diabetic Torii (SDT) rats, a type 2 diabetic rat model. In SDT rats, the plasma glucose level and angiotensin-converting enzyme (ACE) levels were measured, and effects of angiotensin II receptor blocker (ARB) and angiotensin II were also studied. MATERIALS AND METHODS: We evaluated the age-dependent changes in the peripheral and ocular angiotensin II-forming systems in SDT rats at 15 (n = 8), 20 (n = 8), 30 (n = 7), and 50 weeks of age (n = 8). We also evaluated the effect of an ARB (2.5 mg/kg/day candesartan) or angiotensin II (500 ng/kg/min) on retinal gene expressions of VEGF and p22phox, a subunit of NADPH oxidase. RESULTS: The plasma glucose level was significantly increased from 20 weeks of age. No significant changes in ACE activities in the plasma, aorta, and eye were observed until 30 weeks of age. At 50 weeks, ACE activity in the eyes was significantly increased, whereas ACE activities in the plasma and aorta were not. At 50 weeks, significant increases in VEGF and p22phox, an NADPH oxidase subunit, were significantly reduced by candesartan. Angiotensin II infusion resulted in significant increases in VEGF and p22phox levels. CONCLUSIONS: Angiotensin II is involved in the gene expression of VEGF via NADPH oxidase in the retina of SDT rats.
No takes yet. Share an insight, caveat, or question.
Fukumoto et al. (2008) studied Type 2 diabetes (rat model) (n=31). Candesartan or Angiotensin II was evaluated on Retinal gene expressions of VEGF and p22phox. Candesartan significantly reduced VEGF and p22phox gene expression in the retina of 50-week-old diabetic rats, whereas angiotensin II infusion significantly increased these levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: